Please login to the form below

Not currently logged in
Email:
Password:

pharma merger

This page shows the latest pharma merger news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

A round up from pharma, biotech and healthcare. Theresa May looks to enforce ‘soft’ deal on ‘hard’ Brexiteers. ... Takeda to sell Osaka HQ to help cover Shire costs. Takeda’s $63bn purchase of Shire is the biggest pharma merger for some years,

Latest news

  • Shire warms to Takeda’s latest offer, extending deadline Shire warms to Takeda’s latest offer, extending deadline

    Analysts suggest however that negative sentiment could still scupper a deal that is by far the largest ever undertaken by the company - and the biggest in pharma since the $70bn ... Allergan merger in 2015.

  • Pfizer could raise ‘up to $15bn’ from consumer unit sale Pfizer could raise ‘up to $15bn’ from consumer unit sale

    of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit. ... been persistent speculation that it is still looking to complete a mega-merger with

  • Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

    Investors call on the pharma giant to consider a large merger or acquisition deal. ... away from a $160bn merger with Allergan last year, blaming a clampdown on so-called tax inversion deals.

  • Shire completes $32bn Baxalta merger Shire completes $32bn Baxalta merger

    Creates world leading rare diseases specialist. Shire has finalised its $32bn merger with Baxalta, creating one of the world's leading firms specialising in rare diseases and conditions. ... The merger went ahead despite concern new tax inversion rules

  • Shire says Baxalta merger on track despite US tax clampdown Shire says Baxalta merger on track despite US tax clampdown

    Shire has said it is confident its $32bn deal to buy Baxalta will go ahead as planned, despite the abandonment of Pfizer's merger with Allergan. ... While Pfizer and Allergan's $160bn merger was called off this week after the US outlined new plans to

More from news
Approximately 2 fully matching, plus 48 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Reig Jofre boosts Forté Pharma’s senior team Reig Jofre boosts Forté Pharma’s senior team

    Appoints Alain Boutboul as the nutritional supplements group’s general manager. Reig Jofre’s nutritional supplement group Forté Pharma has appointed a new general manager in the form of Alain Boutboul. ... Ignasi Biosca, chief executive officer,

  • Vifor Pharma appoints Dario Eklund Vifor Pharma appoints Dario Eklund

    Vifor Pharma has named Dario Eklund as their head of international business operations. ... Prior to that, he was general manager of Switzerland for Aventis Pharma, until its 2004 merger with Sanofi, and earlier in his career he held a number of

  • Merck & Co appoints new financial head Merck & Co appoints new financial head

    Kellogg had been in the position since joining Merck in 2007 and played a key role in the pharma company's merger with Schering-Plough.

  • Cipher names Gerald McDole as chair Cipher names Gerald McDole as chair

    He has experience at AstraZeneca. Cipher has appointed pharma veteran Gerald McDole as chair of the board of directors. ... Prior to this he was president and CEO of Astra Pharma in Canada before its merger with Zeneca.

  • Merck Serono appoints chief medical officer Merck Serono appoints chief medical officer

    Steven Hildemann joins from Merck & Co. Dr Steven Hildemann has left the US-based Merck &Co to join its German namesake Merck KGaA as chief medical officer of its pharma business ... He joined Merck &Co after the US pharma giant merger with his former

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics